ESMO 2023: Tebentafusp Yields Durable Long-Term Benefits for Patients With Metastatic Uveal Melanoma
ctDNA clearance occurred in 37 percent of evaluable patients treated with tebentafusp
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.